SEC Form 4 · accession 0001179022-17-000075
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard E Uihlein
Director · 10% Owner
Period of report
Dec 14, 2017
Accepted (ET)
Dec 18, 2017 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2017 | A | 14,644 | $2.39 | A | 2,524,553 | D | |
| Common StockF2 | holding | — | — | — | 20,000 | I | By Ed Uihlein Family Foundation |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3 | $2.39 | Dec 14, 2017 | A | 46,875 | A | — | Dec 14, 2027 | Common stock | 46,875 | 46,875 | D |
Explanation of responses
- F1These restricted shares were issued in lieu of cash retainer and meeting fees of $35,000 for 2018. Restrictions on the shares lapse at a rate of 25% per calendar quarter in 2018.
- F2The reporting person is president and director of Ed Uihein Family Foundation, a not-for-profit corporation. The reportion person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for purposes of Section 13(d) of the Securities Exchange Act of 1934.
- F3The options vest 100% on December 14, 2018.